Loading…
KRYS
Krystal Biotech, Inc.
NASDAQ· Healthcare· Biotechnology· CUSIP 501147102
$320.13-0.63%Price as of Oct 23, 00:49 UTC · updated once a day, after the close
At a glance
Krystal Biotech, Inc. (KRYS) is listed on NASDAQ and classified in Biotechnology, part of the Healthcare sector. It is headquartered in Pittsburgh, United States and has 295 employees. The company is worth $9.48B and trades at 40.4x its earnings of the last twelve months; the median for its sector is 24.3x. Revenue was $389.13M in fiscal 2025, up 33.9% from the year before. Net income was $204.83M. The share price is 16.3% below its 52-week high of $382.54. 5 of the 38 superinvestors we track held it at the end of Q2 2026. The largest position belongs to Renaissance Technologies, at $22.18M. In that quarter, 3 of them opened or added to the position. No open-market insider trades in it were filed over the last 30 days.
Written from the data on this page: SEC filings (13F, Form 4, annual reports) and market prices.
Key metrics
- Market cap
- $9.48B
- P/E
- 40.4x
- Forward P/E
- 35.8x
- P/B
- 7.0x
- Dividend yield
- 0.00%
- Payout
- —
- EPS
- $7.93
- ROE
- 20.12%
- Profit margin
- 54.82%
- Revenue growth
- +24.10%
- Beta
- 0.50
- 52-week high
- $382.54
- 52-week low
- $183.03
History
Year by year, from the annual reports; dividends from the payments themselves.
Bars are year-end balances; lines are what happened during the year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Price over time
▲ +293.0% over 5Y.
today you would have $6,320.22▲ +532.0%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 9 closed years, each at that year’s closing price and reported numbers.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $246.54 | $156.66 | $124.06 | $79.22 | $69.95 | $60.00 | $55.38 | $20.78 | $10.52 | |
| P/E | — | 36.0x | 52.2x | 318.1x | — | — | — | — | — | — |
| P/S | 18.5x | 18.5x | 15.5x | 69.2x |
Fair price, seven ways
Seven formulas applied to the reported numbers, each with its assumption next to the result. None of them predicts a price.
Earnings
$90.52
Square root of 22.5 × earnings × book value. Blind to intangibles, so it undervalues software and brands.
Earnings
$198.25
Earnings growing 25.0% a year plus a 0.0% dividend yield. Growth capped at 25%.
Earnings
$192.58
Median P/E of 24.3 among peers in the sector.
Earnings
—
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Cash flow
$237.93
Cash flow growing 15.0% a year for 10 years, discounted at 10%, then 2.5% forever.
Operating
$97.34
Sector median of 14.1x operating profit, less net debt. Banks have no EBITDA.
Dividends
—
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| HSICHenry Schein Inc | $86.00 | 25.1x | 3.0x | 0.00% | 8.86% | $9.58B |
| BIOBio-rad Laboratories Inc | $363.50 | 45.7x | 1.4x | 0.00% | 3.11% | $9.72B |
| BIO.BBio-rad Laboratories Inc | $364.15 | 46.2x | 1.4x | 0.00% | 3.11% | $9.74B |
| KYMRKymera Therapeutics, Inc. | $110.85 |
About the company
- 295
- Pittsburgh, United States
